This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Aug 12;138(6):421-422.

doi: 10.1182/blood.2021011774.

Expanding landscape for relapsed Hodgkin lymphoma

Yun Choi¹, Catherine Diefenbach¹

Affiliations

PMID: 34383039
DOI: 10.1182/blood.2021011774

Comment

Expanding landscape for relapsed Hodgkin lymphoma

Yun Choi et al. Blood. 2021.

. 2021 Aug 12;138(6):421-422.

doi: 10.1182/blood.2021011774.

Authors

Yun Choi¹, Catherine Diefenbach¹

Affiliation

¹ Perlmutter Cancer Center at NYU Langone Health.

PMID: 34383039
DOI: 10.1182/blood.2021011774

No abstract available

PubMed Disclaimer

Comment on

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF. Advani RH, et al. Blood. 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. Blood. 2021. PMID: 33827139 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information